Sugi Predict

Sugi Predict / Compounds / SCHEMBL721179

SCHEMBL721179

SCHEMBL721179

C[CH]c1ccc(OC)c(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.65
▸ TSHR P16473 1/20 0.65
▸ CYP1A1 P04798 7/20 0.59
▸ CYP1B1 Q16678 6/20 0.59
▸ CYP1A2 P05177 3/20 0.59
▸ TUBB4A P04350 1/20 0.59
▸ TUBB P07437 1/20 0.59
▸ TUBA3C P0DPH7 1/20 0.59
▸ TUBA1B P68363 1/20 0.59
▸ TUBA4A P68366 1/20 0.59
▸ TUBB4B P68371 1/20 0.59
▸ TUBB3 Q13509 1/20 0.59
▸ TUBB2A Q13885 1/20 0.59
▸ TUBB8 Q3ZCM7 1/20 0.59
▸ TUBA3E Q6PEY2 1/20 0.59
▸ TUBA1A Q71U36 1/20 0.59
▸ TUBA1C Q9BQE3 1/20 0.59
▸ TUBB6 Q9BUF5 1/20 0.59
▸ TUBB2B Q9BVA1 1/20 0.59
▸ TUBB1 Q9H4B7 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6803522 0.84 AMY1A (0.56) ALDH1A1TSHRTUBB1SMN1; SMN2MAPT
SCHEMBL9431599 0.83 CYP1A1 (0.80) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
SCHEMBL2095590 0.83 ALDH1A1 (0.68) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
SCHEMBL9586847 0.83 CYP1A1 (0.80) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
Methylisoeugenol SCHEMBL1532669 0.82 TYR (0.69) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
Methylisoeugenol SCHEMBL1760676 0.82 TYR (0.69) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
Methylisoeugenol SCHEMBL30203196 0.82 TYR (0.69) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
Methylisoeugenol SCHEMBL112937 0.82 TYR (0.69) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
Methylisoeugenol SCHEMBL29518298 0.82 TYR (0.69) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2
Methylisoeugenol SCHEMBL29364555 0.82 TYR (0.69) ALDH1A1TSHRCYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024052356-A1 INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2024-03-14 — — WO claimed
EP-3050871-B1 NOVEL BIS-AMIDE DERIVATIVE AND USE THEREOF UNIV INDUSTRY COOPERATION GROUP KYUNG HEE UNIV (KR) 2018-11-07 — — EP claimed
US-10064843-B2 Bis-amide derivative and use thereof UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) 2018-09-04 — — US claimed
EP-3303328-A1 AMINOESTER DERIVATIVES Chiesi Farmaceutici S.p.A. (IT) 2018-04-11 — — EP claimed
WO-2016193244-A1 AMINOESTER DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-08 — — WO claimed
US-20160297751-A1 NOVEL BIS-AMIDE DERIVATIVE AND USE THEREOF UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) 2016-10-13 — — US claimed
EP-3050871-A1 NOVEL BIS-AMIDE DERIVATIVE AND USE THEREOF University-Industry Cooperation Group of Kyung Hee University (KR) 2016-08-03 — — EP claimed
US-8906915-B2 Compounds, compositions, and methods for controlling biofilms KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2014-12-09 — — US claimed
US-20130150410-A1 Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-06-13 — — US claimed
US-8399018-B2 Controlled release ion channel modulator compositions and methods for the treatment of otic disorders OTONOMY, INC. (US) 2013-03-19 — — US claimed
EP-0767174-A1 Novel aminoalkanephosphinic acids and their salts CIBA-GEIGY AG (CH) 1997-04-09 — — EP claimed
WO-1996036589-A1 PROCESS FOR PRODUCING N-METHYL-2-(3,4 DIMETHOXYPHENYL)-ETHYLAMINE BASF AKTIENGESELLSCHAFT (DE) 1996-11-21 — — WO claimed
US-5376684-A Aminobutyric acid antagonist; antiepileptic agent CIBA-GEIGY CORPORATION (US) 1994-12-27 — — US claimed
EP-0543780-A2 Novel aminoalkanephosphinic acids and their salts CIBA-GEIGY AG (CH) 1993-05-26 — — EP claimed
US-5034418-A Anticoagulants EISAI CO., LTD. (JP) 1991-07-23 — — US claimed
US-4849434-A PLATELET ACTIVATING FACTOR ANTAGONIST SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1989-07-18 — — US claimed
US-4785010-A AGING RESISTANCE OF HUMANS CASSELLA AKTIENGESELLSCHAFT (DE) 1988-11-15 — — US claimed
EP-0124067-B1 2-(AMINOALKYL)-PYRROLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1986-12-17 — — EP claimed
EP-0124067-A1 2-(Aminoalkyl)-pyrrole derivatives, process for their manufacture and their use CASSELLA Aktiengesellschaft (DE) 1984-11-07 — — EP claimed
US-4029650-A VASODILATORS DELALANDE S. A. (FR) 1977-06-14 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150410-A1 Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders TRPV1, ATP2A1, TRPM2 ALDH1A1 1879/4885TSHR 1758/4885CYP1A1 4464/4885
US-10064843-B2 Bis-amide derivative and use thereof CYP2C8, CYP4F8, CYP2F1 ALDH1A1 1748/4885TSHR 4696/4885CYP1A1 47/4885
US-20160297751-A1 NOVEL BIS-AMIDE DERIVATIVE AND USE THEREOF CYP2C8, CYP4F8, CYP2F1 ALDH1A1 1630/4885TSHR 4654/4885CYP1A1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.